Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Polina R. Grinchik"'
Autor:
Polina R. Grinchik, Leyla S. Namazova-Baranova, Marina V. Fedoseenko, Elena A. Vishneva, Mariya V. Fominykh, Elena D. Makushina, Nina Y. Plenskovskaya, Tatiana E. Privalova, Alexey Yu. Rtishchev, Dina S. Rusinova
Publikováno v:
Вопросы современной педиатрии, Vol 21, Iss 2, Pp 95-104 (2022)
Background. Worldwide private health care system plays significant role in promoting immunization programs for the children population. The role of private medical facilities in Russia in combating children vaccination issues has not been previously
Externí odkaz:
https://doaj.org/article/c41a026dc6b042468b67e8ff1bca9ae5
Autor:
Polina R. Grinchik, Leyla S. Namazova-Baranova, Marina V. Fedoseenko, Asiya A. Girina, Sergey V. Kovalev, Anastasia V. Mazokha, Elena D. Makushina, Elena I. Malinina, Anastasia Yu. Musikhina, Olga A. Perminova, Nina Y. Plenskovskaya, Tatiana E. Privalova, Aleksei Yu. Rtishchev, Dina S. Rusinova, Olga A. Rychkova, Vladislav V. Semerikov, Maria V. Fominykh, Denis S. Fugol, Nadezhda V. Yakimova
Publikováno v:
Педиатрическая фармакология, Vol 19, Iss 1, Pp 6-19 (2022)
Background. One of the effective ways to maintain the epidemic well-being of vaccine preventable diseases is to estimate immunization rates and coverage.Objective. The aim of the study is to conduct comparative analysis of immunization levels among c
Externí odkaz:
https://doaj.org/article/3a6d8d6e5c7d4623ae22f4b975a60823
Autor:
Nikolay I. Briko, Vladimir A. Korshunov, Leyla S. Namazova-Baranova, Juriy V. Lobzin, Alexander A. Baranov, Natalia A. Kostenko, Marina V. Fedoseenko, Elena A. Vishneva, Polina R. Grinchik
Publikováno v:
Вопросы современной педиатрии, Vol 18, Iss 3, Pp 203-211 (2019)
Background. Vaccination of infants with 13-valent pneumococcal conjugate vaccine (PCV) was implemented in national immunization schedule in 2014. In this regard epidemiological monitoring of routine immunization results with vaccination coverage and
Externí odkaz:
https://doaj.org/article/36ab55af288d44eaad38646faee4788c
Publikováno v:
Педиатрическая фармакология, Vol 16, Iss 3, Pp 165-170 (2019)
Relevance. Omalizumab is recommended for treatment of severe forms of recurrent urticaria in children since 12 years old. Though the Omalizumab efficiency and safety in children with recurrent urticaria have not been studied specifically.Objective. T
Externí odkaz:
https://doaj.org/article/23e96fecde034ea99f1d4dbb93cfa6ab